XML 58 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information
 3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Note 14: Segment Information
We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.
 
Three Months Ended
 
March 31,
 
2014
 
2013
Segment revenue—to unaffiliated customers:
 
 
 
Human pharmaceutical products:
 
 
 
Endocrinology
$
1,639.2

 
$
1,724.9

Neuroscience
964.4

 
1,848.8

Oncology
764.3

 
764.2

Cardiovascular
712.8

 
693.9

Other pharmaceuticals
75.0

 
71.1

Total human pharmaceutical products
4,155.7

 
5,102.9

Animal health
527.4

 
499.1

Total segment revenue
$
4,683.1

 
$
5,602.0

Segment profits(1):
 
 
 
Human pharmaceutical products
$
787.8

 
$
1,348.2

Animal health
134.4

 
129.2

Total segment profits
$
922.2

 
$
1,477.4

Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
Segment profits
$
922.2

 
$
1,477.4

Other profits (losses):
 
 
 
Income related to termination of the exenatide collaboration with Amylin (Note 4)
—

 
495.4

Asset impairment, restructuring, and other special charges (Note 5)
(31.4
)
 
(21.7
)
Total consolidated income before taxes
$
890.8

 
$
1,951.1


1
Human pharmaceutical products segment profit includes total depreciation and amortization expense of $325.2 million and $355.7 million for the three months ended March 31, 2014 and 2013, respectively. Animal health segment profit includes total depreciation and amortization expense of $23.6 million and $25.8 million for the three months ended March 31, 2014 and 2013, respectively.
For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.